Print   



For Immediate Release

19 May 2009

ALIZYME PLC

TR - 1:

NOTIFICATION OF MAJOR INTERESTS IN SHARES

1.   Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Alizyme plc

2.    Reason for the notification:

An acquisition or disposal of voting rights

3.    Full name of person(s) subject to the notification obligation:

UBS Investment Bank

4.    Full name of shareholder(s) (if different from 3.):

UBS AG London Branch

5.    Date of the transaction and date on which the threshold is crossed or reached:

15 May 2009

6.    Date on which issuer notified:

19 May 2009

7.    Threshold(s) that is/are crossed or reached:

9.0% 

8.    Notified details:

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE	Situation previous to the Triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights
				Direct	Indirect	Direct	Indirect
Ordinary Shares GB0000374289	18,096,956	18,096,956	20,504,465	20,504,465	-	9.27%	-

  

B: Financial Instruments

Resulting situation after the triggering transaction
Type of financial instrument	Expiration date	Exercise/ Conversion Period/Date	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights
n/a	n/a	n/a	n/a	n/a

Total (A+B)

Number of voting rights	% of voting rights
20,504,465	9.27%

 

9.   Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

 

n/a

Proxy Voting:

10.    Name of the proxy holder:

n/a

11.     Number of voting rights proxy holder will cease to hold:

n/a

12.     Date on which proxy holder will cease to hold voting rights:

n/a

13.    Additional information:

n/a

14.    Contact name:

Nick Blech, Company Secretary

15.    Contact telephone number:

+44 (0) 1223 896000

Further information on Alizyme can be found on the Company's website: www.alizyme.com

ENDHOLXKLFFKEBLBBK